Suppr超能文献

靶向趋化因子以促进肿瘤免疫反应的复杂性。

The Complexity of Targeting Chemokines to Promote a Tumor Immune Response.

机构信息

Columbia Center for Translational Immunology, Columbia University Medical Center, 650 W 168 St. BB-1708, New York, NY, 10032, USA.

出版信息

Inflammation. 2020 Aug;43(4):1201-1208. doi: 10.1007/s10753-020-01235-8.

Abstract

Immunotherapeutic treatment strategies greatly extend patient survival following malignant disease across a wide range of tumor types, including even those with metastatic disease. While diverse in approach, adoptive cell therapy, introduction of T cells that express chimeric antigen receptors, and checkpoint inhibitors all aim to re-invigorate the immune system to promote tumor cell identification and elimination. This review will focus on immune cell infiltration into tumors as well as a cellular organization within the tumor microenvironment as directed by the cell-specific expression patterns of chemokines and chemokine receptors. Through better understanding the chemokine network within tumors, we can uncover mechanisms to promote beneficial immune cell infiltration that can be combined with checkpoint inhibition. Conversely, chemokine expression is not limited to cells of the immune system, and it is understood that tumor cells also express chemokines and chemokine receptors. Tumor cells can hijack the chemokine networks to promote immune suppression and metastatic tumor cell trafficking. We will discuss the ways in which the chemokine network lies at the crossroad of immune evasion and tumor regression. Overall, this review will summarize key publications in the field of immune cell recruitment to tumors, highlight the dichotomous nature of chemokine interventions into cancer, and aims to identify therapeutic pathways forward.

摘要

免疫治疗策略大大延长了恶性肿瘤患者的生存时间,涵盖了广泛的肿瘤类型,包括转移性疾病。尽管方法多种多样,但过继细胞疗法、表达嵌合抗原受体的 T 细胞的引入以及检查点抑制剂都旨在重新激活免疫系统,以促进肿瘤细胞的识别和消除。这篇综述将重点介绍免疫细胞浸润肿瘤以及肿瘤微环境中的细胞组织,这些都是由趋化因子和趋化因子受体的细胞特异性表达模式决定的。通过更好地了解肿瘤内的趋化因子网络,我们可以揭示促进有益免疫细胞浸润的机制,这些机制可以与检查点抑制结合使用。相反,趋化因子的表达不仅局限于免疫系统的细胞,而且已经了解到肿瘤细胞也表达趋化因子和趋化因子受体。肿瘤细胞可以劫持趋化因子网络来促进免疫抑制和转移性肿瘤细胞转移。我们将讨论趋化因子网络位于免疫逃逸和肿瘤消退的十字路口的方式。总的来说,这篇综述将总结免疫细胞招募到肿瘤中的关键出版物,强调趋化因子干预癌症的双重性质,并旨在确定治疗途径。

相似文献

1
The Complexity of Targeting Chemokines to Promote a Tumor Immune Response.
Inflammation. 2020 Aug;43(4):1201-1208. doi: 10.1007/s10753-020-01235-8.
2
Chemokines and Cancer: Friends or Foes?
J Mucosal Immunol Res. 2020;4(1). Epub 2020 Jun 29.
3
Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration.
Theranostics. 2020 May 15;10(14):6231-6244. doi: 10.7150/thno.45219. eCollection 2020.
4
Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.
Immunotherapy. 2022 Apr;14(6):459-473. doi: 10.2217/imt-2021-0228. Epub 2022 Mar 2.
5
A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Front Immunol. 2021 Jul 9;12:688215. doi: 10.3389/fimmu.2021.688215. eCollection 2021.
6
Improving homing in T cell therapy.
Cytokine Growth Factor Rev. 2017 Aug;36:107-116. doi: 10.1016/j.cytogfr.2017.06.009. Epub 2017 Jun 23.
7
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy.
Front Immunol. 2019 Feb 27;10:333. doi: 10.3389/fimmu.2019.00333. eCollection 2019.
8
Chemokine systems in oncology: From microenvironment modulation to nanocarrier innovations.
Int J Biol Macromol. 2024 May;268(Pt 1):131679. doi: 10.1016/j.ijbiomac.2024.131679. Epub 2024 Apr 17.
9
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Signal Transduct Target Ther. 2021 Feb 20;6(1):72. doi: 10.1038/s41392-020-00449-4.
10
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.
Int J Mol Sci. 2021 Sep 10;22(18):9804. doi: 10.3390/ijms22189804.

引用本文的文献

1
Chemokines: humble yet mighty players in the tumour microenvironment.
Front Immunol. 2025 Aug 7;16:1601756. doi: 10.3389/fimmu.2025.1601756. eCollection 2025.
3
FGF19-Activated Hepatic Stellate Cells Release ANGPTL4 that Promotes Colorectal Cancer Liver Metastasis.
Adv Sci (Weinh). 2025 Feb;12(7):e2413525. doi: 10.1002/advs.202413525. Epub 2024 Dec 24.
4
Unlocking the dual role of LSD1 in tumor immunity: innate and adaptive pathways.
Theranostics. 2024 Oct 21;14(18):7054-7071. doi: 10.7150/thno.102037. eCollection 2024.
5
Cracking the Codes behind Cancer Cells' Immune Evasion.
Int J Mol Sci. 2024 Aug 15;25(16):8899. doi: 10.3390/ijms25168899.
7
A dynamic atlas of immunocyte migration from the gut.
Sci Immunol. 2024 Jan 5;9(91):eadi0672. doi: 10.1126/sciimmunol.adi0672.
8
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives.
Pharmaceutics. 2023 Apr 4;15(4):1143. doi: 10.3390/pharmaceutics15041143.
9
Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer.
Front Pharmacol. 2022 Jun 28;13:914730. doi: 10.3389/fphar.2022.914730. eCollection 2022.

本文引用的文献

2
PLCε1 suppresses tumor growth by regulating murine T cell mobilization.
Clin Exp Immunol. 2020 Apr;200(1):53-60. doi: 10.1111/cei.13409. Epub 2020 Jan 9.
3
Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.
Oncoimmunology. 2014 Oct 31;8(10):e947169. doi: 10.4161/21624011.2014.947169. eCollection 2019.
4
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.
Nat Commun. 2019 Sep 5;10(1):4016. doi: 10.1038/s41467-019-11869-4.
6
Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion.
Cancer Res. 2019 Aug 1;79(15):3903-3915. doi: 10.1158/0008-5472.CAN-18-3604. Epub 2019 Jun 12.
9
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
Immunity. 2019 Jun 18;50(6):1498-1512.e5. doi: 10.1016/j.immuni.2019.04.010. Epub 2019 May 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验